argenx (NASDAQ:ARGX) had its target price lifted by Wedbush from $144.00 to $170.00 in a research note released on Friday morning, BenzingaRatingsTable reports. They currently have an outperform rating on the stock.
ARGX has been the topic of several other research reports. Piper Jaffray Companies boosted their price objective on shares of argenx from $161.00 to $182.00 and gave the company an overweight rating in a report on Thursday, May 23rd. Stifel Nicolaus restated a buy rating and issued a $154.00 price objective on shares of argenx in a report on Thursday. ValuEngine lowered shares of argenx from a buy rating to a hold rating in a report on Thursday. Robert W. Baird initiated coverage on shares of argenx in a report on Thursday, June 27th. They issued an outperform rating and a $170.00 price objective on the stock. Finally, Zacks Investment Research lowered shares of argenx from a buy rating to a hold rating in a report on Tuesday, July 16th. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $152.27.
Shares of ARGX stock traded down $1.97 on Friday, hitting $142.61. 125,354 shares of the stock traded hands, compared to its average volume of 113,067. The company’s 50-day moving average price is $140.44. The company has a market capitalization of $4.52 billion, a PE ratio of -60.69 and a beta of 1.18. argenx has a twelve month low of $63.81 and a twelve month high of $150.92.
argenx Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
See Also: S&P 500 Index
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.